

Approved by the Food and Drugs Administration (FDA) in the late 1990s, Celecoxib is a drug that is manufactured and marketed by pharmaceutical giant, Pfizer. More commonly known as Celebrex, this drug is in the group of anti-inflammatory drugs known as cox-2 inhibitors. As with other cox-2 inhibitors, Celebrex was hailed a roaring success and welcomed by medics and patients, even being described as the ‘super aspirin’. Celebrex, like other drugs in its group, was prescribed for inflammation and pain management, and its popularity stemmed from the fact that it could provide the benefits of a traditional non-steroid anti-inflammatory drug without the associated gastric problems.
If so, you may have a possible legal case against the manufacturer of the potentially dangerous drug or medical product. Simply fill out the short form below and an experienced legal expert will contact you as soon as possible!
The recent controversy surrounding the nationally recalled cox-2 inhibitor, Vioxx, has raised questions and concerns about all drugs within this group. Celebrex has already been linked to a number of potentially fatal side effects, such as heart attacks, strokes, and even fatal skin diseases. Medical professional have stated that these dangerous side effects may be the result of Celebrex – and other similar drugs – inhibit the Cox-2 enzyme in the body.
Although concerns about Celebrex and other cox-2 inhibitors have increased over recent months, concerns have been raised over a number of years, since the drug was first introduced and approved by the FDA. As far back as 2001, health groups such as the American Heart Association, the National Stroke Association, and the Arthritis Foundation, were requesting that further testing be carried out by the drug’s manufacturer, which was then Pharmacia Corp, in order to determine what the real and most dangerous risks associated with this drug actually were.

Although heart attacks and strokes are the possible side effects that are of most concern to the majority of people, there are other side effects associated with Celebrex that can also prove dangerous. These include: gastric hemorrhaging, kidney problems, allergies, abdominal pains, nausea, weight problems, inflammation, skin problems, and fatigue amongst others. As time goes on, testing spears to show that the benefits of this drug come at a very high price, and since most people are unwilling to pay this price – and were unaware of the risks associated with Celebrex in the first place – a vast number of lawsuits and compensation claims is likely to stem from the controversy over these cox-2 inhibitors.
Some patients have already started looking into legal action even though testing on celebrex is still underway. Lawyers that specialize within this field are anticipating a large number of claims and lawsuits, and are offering advice to patients and victims’ relatives with regards to filing either class action or individual Celebrex lawsuits. Those that have suffered adverse effects from Celebrex are advised to seek assistance from a lawyer that specializes in drug litigation, as these professional will be well versed, experienced and skilled at putting together watertight cases for plaintiffs.
Although, unlike Vioxx, Celebrex has not been pulled from the US market, many feel that it is simply a matter of time, despite the drug manufacturer Pfizer’s claims that this drug does not hold the same dangers as Vioxx. Should this happen, the number of cases being filed is likely to increase dramatically, and many firms are now offering specialist legal assistance from drug litigation professionals. Whether you are interested in filing and individual claim, or whether you wish to find out more about class action proceedings, the earlier you contact an experienced lawyer within this field, the greater your chances of filing a successful Celebrex claim for harm or injury caused by this drug. Patients are advised to educate themselves on the risks of Celebrex and other cox-2 inhibitors, and to remain vigilant for any signs of these effects.